Lexicon Pharmaceuticals I... (LXRX)
0.68
-0.01 (-1.72%)
At close: Jan 15, 2025, 1:26 PM
Company Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.
Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.
The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc.
Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Apr 7, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 285 |
| CEO | Dr. Michael Exton Ph.D. |
Contact Details
Address: 2445 Technology Forest Boulevard The Woodlands, Texas United States | |
| Website | https://www.lexpharma.com |
Stock Details
| Ticker Symbol | LXRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001062822 |
| CUSIP Number | 528872302 |
| ISIN Number | US5288723027 |
| Employer ID | 76-0474169 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Exton Ph.D. | Chief Executive Officer & Director |
| Scott M. Coiante | Chief Financial Officer & Senior Vice President |
| Brian T. Crum | Senior Vice President, General Counsel & Secretary |
| Carrie Siragusa | Vice President of Marketing |
| Desiree Gendron | Vice President of Sales & Training |
| Dixon Terry | Vice President of Compliance |
| Dr. Alan J. Main Ph.D. | Executive Vice President of Innovation & Chemical Sciences |
| Dr. Craig B. Granowitz M.D., Ph.D. | Senior Vice President & Chief Medical Officer |
| Kristen L. Alexander | Vice President of Finance & Accounting |
| Lisa M. DeFrancesco | Vice President of Investor Relations & Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 07, 2025 | 8-K | Current Report |
| Jan 02, 2025 | 4 | Filing |
| Jan 02, 2025 | 3 | Filing |
| Jan 02, 2025 | 8-K | Current Report |
| Dec 16, 2024 | 3 | Filing |
| Dec 09, 2024 | SC 13D/A | [Amend] Filing |
| Dec 02, 2024 | 4 | Filing |
| Dec 02, 2024 | 3 | Filing |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 8-K | Current Report |